Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

HIV medicine - 1 Oct 2008

Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C

Abstract excerpt

OBJECTIVES: Recent data showed the selection of mutations in the integrase gene, mainly involving position 148 or 155, in patients displaying virological failure (VF) on raltegravir (RAL) therapy. Here, we describe the development of RAL resistance, in both plasmatic and cellular compartments, in three heavily pretreated HIV-infected patients failing RAL-containing regimens. METHODS: Three of 17 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Salvage Therapy

Share to Treatment Failure

Source

Identifiers

PMID: 18651855
DOI: 10.1111/j.1468-1293.2008.00628.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.PMID 18651855Read ↗

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.Semantic proximity Read ↗

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.Semantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.Semantic proximity Read ↗

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.Semantic proximity Read ↗

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.Semantic proximity Read ↗

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Semantic proximity Read ↗

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.